Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Net Cash Flow (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Net Cash Flow data on record, last reported at -$1.5 million in Q3 2025.

  • For Q3 2025, Net Cash Flow fell 115.92% year-over-year to -$1.5 million; the TTM value through Sep 2025 reached -$5.9 million, down 429.51%, while the annual FY2024 figure was $18.5 million, 156.8% up from the prior year.
  • Net Cash Flow reached -$1.5 million in Q3 2025 per ASMB's latest filing, down from $593000.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $18.8 million in Q1 2021 and bottomed at -$25.1 million in Q4 2021.
  • Average Net Cash Flow over 5 years is -$1.9 million, with a median of -$1.1 million recorded in 2024.
  • The widest YoY moves for Net Cash Flow: up 526.9% in 2021, down 2318.27% in 2021.
  • A 5-year view of Net Cash Flow shows it stood at -$25.1 million in 2021, then soared by 91.03% to -$2.3 million in 2022, then crashed by 202.22% to -$6.8 million in 2023, then soared by 245.15% to $9.9 million in 2024, then tumbled by 114.88% to -$1.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$1.5 million in Q3 2025, $593000.0 in Q2 2025, and -$14.9 million in Q1 2025.